Enlisting the AIDS virus to fight cancer

August 29, 2012
Infographic representation of the HIV contamination process. © CNRS Photothèque/www.gregcirade.com

(Medical Xpress)—Can HIV be transformed into a biotechnological tool for improving human health? According to a CNRS team at the Architecture et Réactivité de l'ARN (RNA Architecture and Reactivity) laboratory, the answer is yes. Taking advantage of the HIV replication machinery, the researchers have been able to select a specific mutant protein. Added to a culture of tumor cells in combination with an anticancer drug, this protein improves the effectiveness of the treatment at 1/300 the normal dosage levels. Published in PLoS Genetics on 23 August 2012, these findings could lead to long-term therapeutic applications in the treatment of cancer and other pathologies.

The (HIV), which causes AIDS, uses human cell material to multiply, primarily by inserting its genetic material into the host cells' genome (see illustration below). The distinctive characteristic of HIV is that it mutates constantly, and consequently generates several mutant proteins (or variants) in the course of its successive multiplications. This phenomenon allows the virus to adapt to repeated environmental changes and resist the antiviral treatments that have been developed so far.

At the IBMC (Institut de Biologie Moléculaire et Cellulaire) in Strasbourg, the researchers of the CNRS Architecture et Réactivité de l'ARN laboratory had the idea of using this multiplication strategy to rechannel the effects of the virus for therapeutic purposes, in particular the treatment of cancer.

They first altered the by introducing a human gene that is found in all cells: the gene for deoxycytidine kinase (dCK), a protein that activates anticancer drugs.  Researchers have been trying to produce a more effective form of dCK for several years. Through HIV multiplication, the CNRS team has selected a "library" of nearly 80 mutant proteins and tested them on tumor cells in the presence of an anticancer drug. The results have enabled them to identify a dCK variant that is more effective than the wild-type (non-mutated) protein, inducing the death of tumor cells in culture. In combination with this protein, the anticancer drugs showed identical effectiveness at 1/300 the dose. The possibility of reducing the doses of anticancer drugs would palliate the problems posed by their components' toxicity, reduce their side effects and, most importantly, improve their effectiveness.

One advantage of this experimental technique is that the mutant proteins were tested directly on cells in culture. The next step in the years to come will be preclinical (animal) studies on the isolated . In addition, this experimental system using a normally life-threatening virus is likely to lead to a great many other therapeutic applications.

Explore further: Study: Cells have a natural defense against HIV

More information: Retrovolution: HIV-driven Evolution of Cellular Genes and Improvement of Anticancer Drug Activation, Rossolillo P., Winter F., Simon-Loriere E., Gallois-Montbrun S. and Negroni M. PLoS Genetics, 23 August 2012.

Related Stories

Study: Cells have a natural defense against HIV

March 14, 2006

Scientists here have discovered a previously unknown mechanism that cells use to fight off the human immunodeficiency virus (HIV), the cause of AIDS. The findings indicate that two proteins that normally help repair cellular ...

Mutant host cell protein sequesters critical HIV-1 element

January 15, 2009

Scientists have identified a new way to inhibit a molecule that is critical for HIV pathogenesis. The research, published by Cell Press in the January 16th issue of the journal Molecular Cell, presents a target for development ...

Insight into structure of HIV protein could aid drug design

June 9, 2010

Researchers at the University of Iowa Carver College of Medicine and University of Nebraska Medical Center (UNMC) have created a three-dimensional picture of an important protein that is involved in how HIV -- the virus responsible ...

Recommended for you

Researchers discover otulipenia, a new inflammatory disease

August 22, 2016

National Institutes of Health researchers have discovered a rare and sometimes lethal inflammatory disease - otulipenia - that primarily affects young children. They have also identified anti-inflammatory treatments that ...

Solving the mystery of meningiomas reveals a surprise twist

August 23, 2016

In solving one mystery—the genetic roots of benign brain tumors called meningiomas—a team of scientists led by Yale researchers stumbled upon an even greater one: How is it possible that two of the mutations linked to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.